CHICAGO TRUST Co NA Trims Stake in Edwards Lifesciences Co. (NYSE:EW)

CHICAGO TRUST Co NA lessened its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 9.1% during the 4th quarter, HoldingsChannel reports. The fund owned 5,662 shares of the medical research company’s stock after selling 570 shares during the quarter. CHICAGO TRUST Co NA’s holdings in Edwards Lifesciences were worth $419,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of EW. FSA Wealth Management LLC bought a new stake in Edwards Lifesciences during the 3rd quarter worth approximately $30,000. Prospera Private Wealth LLC purchased a new stake in shares of Edwards Lifesciences in the third quarter worth $32,000. Avior Wealth Management LLC raised its position in shares of Edwards Lifesciences by 138.7% during the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 308 shares during the period. Peoples Bank KS purchased a new position in shares of Edwards Lifesciences during the 3rd quarter valued at $40,000. Finally, JFS Wealth Advisors LLC boosted its holdings in Edwards Lifesciences by 31.1% in the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock worth $46,000 after buying an additional 166 shares during the period. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of Edwards Lifesciences stock opened at $71.20 on Tuesday. The stock has a 50 day moving average price of $71.73 and a 200-day moving average price of $71.77. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12. The stock has a market cap of $41.99 billion, a price-to-earnings ratio of 10.27, a price-to-earnings-growth ratio of 3.61 and a beta of 1.11. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting the consensus estimate of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The company had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. During the same period in the previous year, the firm earned $0.59 earnings per share. Edwards Lifesciences’s quarterly revenue was up 8.9% compared to the same quarter last year. Equities analysts expect that Edwards Lifesciences Co. will post 2.56 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have commented on EW. Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and raised their price target for the company from $82.00 to $90.00 in a report on Monday, December 16th. Robert W. Baird lowered their price target on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. Daiwa America downgraded Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 30th. Piper Sandler reduced their price objective on shares of Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. Finally, Royal Bank of Canada upped their target price on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the stock an “outperform” rating in a research report on Thursday, December 5th. Sixteen analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $79.40.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 25,000 shares of the company’s stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the transaction, the insider now owns 198,526 shares of the company’s stock, valued at $13,084,848.66. This represents a 11.18 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total value of $327,850.00. Following the sale, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,077,593.52. This trade represents a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 32,500 shares of company stock worth $2,160,800. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.